



8-29-7

1626
JPR

427.100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: :
Marie-Odile Galcera Contour, et al. : Group: 1626
Serial No.: 10/562,949 :
Filed: February 10, 2006 : Examiner: Cheng, Karen
For: BENZOTHAZOLE.. PROCESSES :
Hedman and Costigan
1185 Avenue of the Americas
New York, NY 10036
August 28, 2007

SUPPLEMENTAL RESPONSE


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Supplemental to the amendment of July 20, 2007, Applicants are submitting herewith a sworn English translation of French priority Serial No. 03 07648 filed June 25, 2003 which removes the Galcera Contour et al. reference which has a publication date of July 10, 2003.

Therefore, it is believed that the application is now in condition for allowance and favorable reconsideration of the application is requested.

Respectfully submitted,
Hedman and Costigan


Charles A. Muserlian #19,683
Attorney for Applicants
Tel. 212 302 8989

CAM:mlp
Enclosures



"EXPRESS MAIL" Mailing Label Number: EQ 608 567 615 US

Date of Deposit: AUG. 28, 2007

I hereby certify that this correspondence is being deposited with the United States
Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" Service under 37
CFR 1.10 on the date indicated above and is addressed to the Commissioner for
Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Marie-Louise Pinset
Marie-Louise Pinset

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF TRANSLATION

Honourable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

I, JOHN CHARLES McGILLEY, B.A. M.I.T.I., Technical Translator, of c/o
Priory Translations Limited, 11, Magdalen Street, Colchester, Essex, England,
hereby state:

THAT I am well acquainted with the French and English languages.

THAT I translated the document identified as French Patent Application No.
03 07648 filed at the National Institute of Industrial Property on 25th June 2003,
from French into English;

THAT the attached English translation is a true and correct translation of
French Patent Application No. 03 07648 .

to the best of my knowledge and belief; and

THAT all statements made of my own knowledge are true and that all
statements made on information and belief are believed to be true and further,
that these statements are made with the knowledge that wilful false statements
and the like are punishable by fine or imprisonment, or both, under Section 1001
of Title 18 of the United States Code





JOHN CHARLES McGILLEY

FRENCH REPUBLIC

inpi

NATIONAL INSTITUTE
OF INDUSTRIAL PROPERTY

Patent of invention

Utility certificate

OFFICIAL COPY

The Director General of the National Institute of Industrial Property certifies that the document annexed hereto is the certified true copy of an application for title of industrial property registered at the Institute.

Drawn up in Paris, 20th July 2007

For the Director General
of the National Institute
of Industrial Property
The Head of the Patent Department

Martine PLANCHE

INPI
National Institute
of Industrial Property

26 bis, rue de Saint Petersburg
 75800 Paris Cedex 08
 Tel: 01 53 04 53 04 Fax: 01 42 94 86 54

PATENT OF INVENTION
Utility certificate *cerfa No 11354 01*
 Intellectual property code – Book VI
Request for grant 1/2

Important The second page must be completed

For INPI use only

This form must be completed clearly in black ink

Delivery of documents Date 25th June 2003 Place 75 INPI Paris National Registration No. 0307648 assigned by INPI Date of filing assigned by INPI 25th June 2003 Your references for this file (optional) RS 337 – ER/MM		1. Name and address of applicant or representative to whom correspondence should be addressed Monsieur André BOURGOUIN BEAUFOR IPSEN - S.C.R.A.S. Direction de la Propriété Industrielle 24 rue Erlanger 75781 PARIS CEDEX 16
Confirmation of a filing by fax <input type="checkbox"/> no. assigned by INPI to the fax		
2. NATURE OF APPLICATION		Tick one of the following 4 boxes
Patent application		<input checked="" type="checkbox"/>
Application for utility certificate		<input type="checkbox"/>
Divisional application <i>Initial patent application</i> <i>or initial application for utility certificate</i>		<input type="checkbox"/> No. Date / / No. Date / /
Conversion of a European patent application <i>Initial patent application</i>		<input type="checkbox"/> No. Date / /
3. TITLE OF INVENTION (200 characters or spaces maximum) Benzothiazole-4,7-diones and benzooxazole-4,7-diones substituted in position 5 or 6 and processes for their preparation		
4. DECLARATION OF PRIORITY OR REQUEST FOR BENEFIT FROM THE FILING DATE OF A PREVIOUS FRENCH APPLICATION		Country or organisation Date: / / No. Country or organisation Date: / / No. Country or organisation Date: / / No. <input type="checkbox"/> If there are other priorities, tick the box and use the printed form "Continuation"
5. APPLICANT		<input type="checkbox"/> If there are other applicants, tick the box and use the printed form "Continuation"
Name or title of company		SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.)
First names		
Legal form		Simplified joint stock company
SIREN no.		308197185
APE-NAF code		741J
Address	Street	42 rue du Docteur Blanche
	Post code and town	75016 PARIS
Country		FRANCE
Nationality		French
Telephone no. (optional)		(33) 01 44 30 43 43
Fax no. (optional)		(33) 01 44 30 43 21
Email address (optional)		

INPI
National Institute
of Industrial Property

PATENT OF INVENTION
Utility certificate
Request for grant 2/2

For INPI use only

Presentation of documents		
Date	25th June 2003	
Place	75 INPI Paris	
National Registration no. 0307648 assigned by INPI		
Your references for this file: (optional)		RS 337 – ER/MM
6. REPRESENTATIVE		
Name		BOURGOUIN
First name		André
Office or company		BEAUFOR IPSEN - S.C.R.A.S. Direction de la Propriété Industrielle
No. of permanent power of attorney and/or contractual relationship		PG 11878
Address	Street	24 rue Erlanger
	Post code and town	75781 PARIS CEDEX 16
Telephone no. (optional)		(33) 01 44 55 96 10 10
Fax no. (optional)		(33) 01 44 55 96 13 42
Email address (optional)		andre.bourgouin@beaufour-ipsen.com
7. INVENTOR(S)		
The inventors are the applicants		<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No In this case, supply a separate designation of inventor(s)
8. SEARCH REPORT		
Immediate establishment or deferred establishment		<input checked="" type="checkbox"/> <input type="checkbox"/>
Payment of fee in instalments		Payment in two instalments, only for natural persons <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
9. REDUCTION IN LEVEL OF FEES		Only for natural persons <input type="checkbox"/> Requested for the first time for this invention (attach a notice of no charge) <input type="checkbox"/> Requested prior to this filing (attach a copy of the decision of acceptance for this invention or indicate its reference no.):
If you have used the printed form "Continuation", indicate the number of pages attached		
10. SIGNATURE OF APPLICANT OR REPRESENTATIVE: (name and capacity of signatory)		STAMP OF PREFECTURE OR INPI
André BOURGOUIN, Representative		Mme BLANCANEUX

The law no.78-17 of 6th January 1978 relating to data processing, files and freedoms applies to the replies given on this form. It guarantees the right of access and rectification for the data held about you with the INPI.

Benzothiazole-4,7-diones and benzooxazole-4,7-diones substituted in position 5 or 6 and their preparation processes

5 A subject of the present invention is certain derivatives of benzothiazole-4,7-diones and benzooxazole-4,7-diones substituted in position 5 or in position 6, which inhibit the Cdc25 phosphatases, in particular the Cdc25-C phosphatase, and/or the CD45 phosphatase as well as a process for the preparation of such derivatives and of the synthesis intermediates useful in the implementation of this process.

10 Control of the transition between the different phases of the cell cycle during mitosis or meiosis is ensured by a group of proteins the enzyme activities of which are associated with different states of phosphorylation. These states are controlled by two large classes of enzymes: the kinases and the phosphatases.

15 Synchronization of the different phases of the cell cycle thus allows reorganization of the cell architecture at each cycle in the whole of the living world (microorganisms, yeasts, vertebrates, plants). Among the kinases, the cyclin-dependent kinases (CDKs) play a major role in this control of the cell cycle. The enzyme activity of these different CDKs is controlled by two other families of enzymes which work in opposition (Jesus and Ozon, *Prog. Cell Cycle Res.* (1995), **1**, 215-228). The first includes kinases such as Wee1 and Mik1 which deactivate the CDKs by phosphorylating certain amino acids (Den Haese et al., *Mol. Biol. Cell* (1995), **6**, 371-385). The second includes phosphatases such as Cdc25 which activate the CDKs by dephosphorylating tyrosine and threonine residues of CDKs (Gould et al., *Science* (1990), **250**, 1573-1576).

20 The phosphatases are classified in 3 groups: the serine/threonine phosphatases (PPases), the tyrosine phosphatases (PTPases) and the dual-specificity phosphatases (DSPases). These phosphatases play an important role in the regulation of numerous cell functions.

25 As regards human Cdc25 phosphatases, 3 genes (Cdc25-A, Cdc25-B and Cdc25-C) code for the Cdc25 proteins. Moreover, variants originating from alternative splicing of the Cdc25B gene have been identified (cf. for example Baldin et al., *Oncogene* (1997), **14**, 2485-2495).

The role of the Cdc25 phosphatases in oncogenesis is now better known and the action mechanisms of these phosphatases are illustrated in particular in the following

references: Galaktionov et al., *Science* (1995), **269**, 1575-1577; Galaktionov et al., *Nature* (1996), **382**, 511-517; and Mailand et al., *Science* (2000), **288**, 1425-1429.

In particular, the overexpression of the different forms of Cdc25 is now reported in numerous series of human tumors:

- 5 - Breast cancer: cf. Cangi et al., *Résumé 2984, AACR meeting San Francisco*, 2000);
- Lymphomas: cf. Hernandez et al., *Int. J. Cancer* (2000), **89**, 148-152 and Hernandez et al., *Cancer Res.* (1998), **58**, 1762-1767;
- Cancers of the neck and head: cf. Gasparotto et al., *Cancer Res.* (1997), **57**, 2366-2368.

- 10 Moreover, E. Sausville's group reports an inverse correlation between the level of expression of Cdc25-B in a panel of 60 lines and their sensitivities to CDK inhibitors, suggesting that the presence of Cdc25 can bring a resistance to certain antineoplastic agents and more particularly to CDK inhibitors (Hose et al., *Proceedings of AACR, Abstract 3571*, San Francisco, 2000).

- 15 Among other targets, the pharmaceutical industry is therefore at present researching compounds capable of inhibiting the Cdc25 phosphatases in order to use them in particular as anti-cancer agents.

- The Cdc25 phosphatases also play a role in neurodegenerative diseases such as Alzheimer's disease (cf. Zhou et al., *Cell Mol. Life Sci.* (1999), **56**(9-10), 788-806; Ding
- 20 et al., *Am. J. Pathol.* (2000), **157**(6), 1983-90; Vincent et al., *Neuroscience* (2001), **105**(3), 639-50) in such a manner that it is also possible to envisage using compounds possessing an inhibition activity on these phosphatases in order to treat these diseases.

Another problem addressed by the invention is research into medicaments intended to prevent or treat the rejection of organ transplants or also to treat auto-immune diseases.

- 25 In these disorders/diseases, the non-appropriate activation of lymphocytes and monocytes/macrophages is involved. The immunosuppressive medicaments known at present have side effects which could be diminished or modified by products specifically targeting the signalling pathways in hematopoietic cells which initiate and maintain inflammation.

- 30 The CD45 phosphatase plays a crucial role in the transmission of signals from receptors on the T lymphocytes by regulating the phosphorylation and the activity of the tyrosine

kinases of the src family, the negative regulation sites p56^{lck} and p59^{fyn} of which it is capable of dephosphorylating.

5 The CD45 phosphatase is therefore a potential target in the treatment of immune diseases. In fact, the blocking of the CD45 phosphatase by an anti-CD45 antibody inhibits the activation of the T lymphocytes *in vitro* (Prickett and Hart, *Immunology* (1990), **69**, 250-256). Similarly, the T lymphocytes of transgenic mice not expressing CD45 (CD45 *knock-out mice*) do not respond to stimulation by an antigen (Trowbridge and Thomas, *Annu. Rev. Immunol.* (1994), **12**, 85-116).

10 Moreover, CD45 would be capable of dephosphorylating a sub-unit associated with Lyn, which would trigger a flow of calcium and activation of the mastocytes. Hamaguchi et al. (*Bioorg. Med. Chem. Lett.* (2000), **10**, 2657-2660) have shown that a particular CD45 inhibitor (with an IC₅₀ equal to 280 nM) would suppress the release of histamine from rat peritoneal mastocytes and would protect mice from anaphylactic shock.

15 The advantage of finding CD45 phosphatase inhibitors would therefore appear obvious in particular when there is interest in:

- obtaining an immunosuppressive effect in general, and in particular:

20 • within the scope of the treatment of auto-immune diseases (Zong et al., *J. Mol. Med.* (1998), **76**(8), 572-580) such as for example multiple sclerosis or autoimmune encephalitis (Yacyshyn et al., *Dig. Dis. Sci.* (1996), **41**(12), 2493-8) and diabetes (Shimada et al., *J. Autoimmun.* (1996), **9**(2), 263-269);

• within the scope of the treatment of transplant rejections;

- in the treatment of inflammation in general, and in particular:

25 • within the scope of the treatment of arthritis (Pelegri et al., *Clin. Exp. Immunol.* (2001), **125**(3), 470-477), rheumatoid arthritis, rheumatic diseases, conjunctivitis (Iwamoto et al., *Graefes Arch. Clin. Ophthalmol.* (1999), **237**(5), 407-414) and pruritic diseases;

30 • within the scope of the treatment of digestive inflammatory diseases such as for example Crohn's disease (Yacyshyn et al., *Dig. Dis. Sci.* (1996), **41**(12), 2493-2498), haemorrhagic rectocolitis and hepatitis (Volpes et al., *Hepatology* (1991), **13**(5), 826-829); and

- in the treatment of allergies (Pawlik et al., *Tohoku J. Exp. Med.* (1997), **182**(1), 1-8).


5 The invention offers novel Cdc25 phosphatase inhibitors (in particular Cdc25-C phosphatase inhibitors), and/or CD45 phosphatase inhibitors, which are derivatives of benzothiazole-4,7-diones and benzoxazole-4,7-diones corresponding to the general formula **(I)** defined hereafter. Given the above, these compounds are capable of being used as medicaments, in particular in the treatment of the following diseases/disorders:

- inhibition of tumorous proliferation alone or in combination with other treatments;
- inhibition of normal cell proliferation alone or in combination with other treatments;
- 10 • neurodegenerative diseases such as Alzheimer's disease;
- prevention of spontaneous alopecia;
- prevention of alopecia induced by exogenous products;
- prevention of radiation-induced alopecia;
- prevention of spontaneous or induced apoptosis of normal cells;
- 15 • prevention of meiosis and fertilization;
- prevention of the maturation of oocytes;
- all the diseases/all the disorders corresponding to uses reported for CDK inhibitors, and in particular non-tumorous proliferative diseases (for example: angiogenesis, psoriasis or restenosis), tumorous proliferative diseases, parasitology (proliferation of protozoans), viral infections, neurodegenerative diseases, myopathies;
- 20 • all the diseases/all the disorders corresponding to clinical uses of vitamin K and its derivatives;
- autoimmune diseases such as for example multiple sclerosis and rheumatoid arthritis; and
- 25 • diabetes.

Moreover, the compounds of the present invention are also, due to their Cdc25 phosphatase inhibition properties, capable of being used to inhibit the proliferation of microorganisms, in particular yeasts. One of the advantages of these compounds is their low toxicity on healthy cells.

30 A certain number of derivatives of benzothiazole-4,7-diones and benzoxazole-4,7-diones are already known.

In particular, the patent GB 1 534 275 relates to herbicides, the active ingredient of which is a compound corresponding to one of the general formulae



in which:

R¹ represents in particular a hydrogen atom or an alkyl or cycloalkyl radical;


5 R² represents in particular a hydrogen atom, an alkyl or cycloalkyl radical;

X represents in particular a halogen atom or an alkoxy radical;

Y and Z can in particular represent together with the carbon atoms which carry them a thiazole ring optionally substituted by an alkyl radical; and

R represents in particular an alkyl radical.

10 Moreover, the Patent Application PCT WO 99/32115 described the compounds of general formula (A3)



in which:

the substituents R²-R⁶ are chosen from the group constituted by a hydrogen atom, electron-donating substituents, electron-attracting substituents and electron-modulating substituents;


15

and Y⁵ and Y⁶ are in particular chosen from the group constituted by a hydrogen atom, electron-donating substituents, electron-attracting substituents and electron-modulating substituents.

In the Patent Application PCT WO 99/32115, the term “electron-donating substituent” refers to a functional group having a tendency to donate electronic density; the substituents alkyl, alkenyl and alkynyl are mentioned. Throughout this Patent Application, “electron-attracting substituent” refers to a functional group having a tendency to attract electronic density; the substituents cyano, acyl, carbonyl, fluoro, nitro, sulphonyl and trihalomethyl are mentioned. Finally, an “electron-modulating substituent” is defined in this Application as a functional group having a tendency to modulate the electronic density, which can both attract and donate electrons and is therefore such that it can stabilize a cationic intermediate in an aromatic electrophilic substitution reaction; a functional group including, for example, amino substituents (for example -NH₂, alkylamino or dialkylamino), hydroxy, alkoxy or aryl, heterocyclic substituents, halogen atoms, etc. are mentioned.

The compounds of general formula (A3) are presented as modulators of the ryanodine receptors which can be used as pesticides or as therapeutic agents, for example in the treatment of congestive cardiac failure, migraine headaches, hypertension, Parkinson's disease or Alzheimer's disease or in the prevention of miscarriage.

Finally, the derivatives of benzoxazole-4,7-diones of general formula (A4)




(A4)

in which:

Ar¹ represents an optionally substituted aryl radical,
each of Ar² and Ar³ represents a hydrogen atom or an optionally substituted aryl radical,
and

each of Q¹ and Q² represents in particular O,
are described as active constituents of photosensitive layers of photoreceptors.

In the Patent Application PCT/FR02/04544, the Applicant has described the compounds corresponding to general formula (I)



(I)

in which:

- 5 R^1 represents a hydrogen atom or an alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, $-(CH_2)-X-Y$, $-(CH_2)-Z-NR^5R^6$ radical or a $-CHR^{35}R^{36}$ radical in which R^{35} and R^{36} form together with the carbon atom which carries them an indanyl or tetralinyl radical, or also R^{35} and R^{36} form together with the carbon atom which carries them a saturated heterocycle containing 5 to 7 members and 1 to 2 heteroatoms chosen from O, N and S, the nitrogen atoms of said heterocycle being optionally substituted by radicals chosen
- 10 from the alkyl radicals and the benzyl radical,
 R^1 also being able, when W represents O, to represent moreover a carbocyclic aryl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl or alkoxy radical,
 X representing a bond or a linear or branched alkylene radical containing 1 to 5 carbon
- 15 atoms,
 Y representing a saturated carbon-containing cyclic system containing 1 to 3 condensed rings chosen independently from rings with 3 to 7 members, or Y representing a saturated heterocycle containing 1 to 2 heteroatoms chosen independently from O, N and S and attached to the X radical by an N or CH member, said saturated heterocycle
- 20 moreover containing 2 to 6 additional members chosen independently from $-CHR^7-$, $-CO-$, $-NR^8-$, $-O-$ and $-S-$, R^7 representing a hydrogen atom or an alkyl radical and R^8 representing a hydrogen atom or an alkyl or aralkyl radical, or also Y representing a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 3 times by substituents chosen independently from the group constituted by a halogen atom, an
- 25 alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, the phenyl radical, an SO_2NHR^9 and an $NR^{10}R^{11}$ radical, R^9 representing a hydrogen atom or an alkyl or phenyl radical, and R^{10} and R^{11} independently representing alkyl radicals,

Z representing a bond or a linear or branched alkylene radical containing 1 to 5 carbon atoms,

R⁵ and R⁶ being chosen independently from a hydrogen atom, an alkyl, aralkyl or -(CH₂)_n-OH radical in which n represents an integer from 1 to 6,

5 or R⁵ representing an alkoxycarbonyl, haloalkoxycarbonyl or aralkoxycarbonyl radical and R⁶ representing a hydrogen atom or a methyl radical,

or also R⁵ and R⁶ forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the -CR¹²R¹³-, -O-, -S- and
10 -NR¹⁴- radicals, R¹² and R¹³ independently representing each time that they occur a hydrogen atom or an alkyl radical, and R¹⁴ representing a hydrogen atom or an alkyl or aralkyl radical, or also R¹⁴ representing a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,

15 R² representing a hydrogen atom or an alkyl or aralkyl radical;
or also R¹ and R² forming together with the nitrogen atom a heterocycle with 4 to 8 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the -CR¹⁵R¹⁶-, -O-, -S- and
-NR¹⁷- radicals, R¹⁵ and R¹⁶ independently representing each time that they occur a
20 hydrogen atom or an alkyl radical, and R¹⁷ representing a hydrogen atom or an alkyl or aralkyl radical;

R³ represents a hydrogen atom, a halogen atom, or an alkyl, haloalkyl, alkoxy or alkylthio radical;

R⁴ represents an alkyl, cycloalkyl, cycloalkylalkyl, cyano, amino,
25 -CH₂-COOR¹⁸, -CH₂-CO-NR¹⁹R²⁰ or -CH₂-NR²¹R²² radical, or R⁴ represents a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 4 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl, alkoxy, haloalkoxy or NR³⁷R³⁸ radical, or also R⁴ represents a phenyl radical possessing two substituents which form together a methylenedioxy or ethylenedioxy radical,

30 R¹⁸ representing a hydrogen atom or an alkyl radical,
R¹⁹ representing a hydrogen atom, an alkyl radical or an aralkyl radical the aryl group of which is optionally substituted 1 to 3 times by substituents chosen independently from the group constituted by a halogen atom, an alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, the
35 phenyl radical, an SO₂NHR²³ radical and an NR²⁴R²⁵ radical, R²³ representing a

hydrogen atom or an alkyl or phenyl radical, and R^{24} and R^{25} independently representing alkyl radicals,

R^{20} representing a hydrogen atom or an alkyl radical,

or also R^{19} and R^{20} forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the $-CR^{26}R^{27}-$, $-O-$, $-S-$ and $-NR^{28}-$ radicals, R^{26} and R^{27} independently representing each time that they occur a hydrogen atom or an alkyl radical, and R^{28} representing a hydrogen atom or an alkyl or aralkyl radical, or also R^{28} representing a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,

R^{21} representing a hydrogen atom, an alkyl radical or an aralkyl radical the aryl group of which is optionally substituted 1 to 3 times by substituents chosen independently from the group constituted by a halogen atom, an alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, the phenyl radical, an SO_2NHR^{29} radical and an $NR^{30}R^{31}$ radical, R^{29} representing a hydrogen atom or an alkyl or phenyl radical, and R^{30} and R^{31} independently representing alkyl radicals,

R^{22} representing a hydrogen atom or an alkyl radical,

or also R^{21} and R^{22} forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the $-CR^{32}R^{33}-$, $-O-$, $-S-$ and $-NR^{34}-$ radicals, R^{32} and R^{33} independently representing each time that they occur a hydrogen atom or an alkyl radical, and R^{34} representing a hydrogen atom, an alkyl or aralkyl radical, or also R^{34} representing a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,

R^{37} and R^{38} being chosen independently from a hydrogen atom and an alkyl radical or R^{37} and R^{38} forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the $-CR^{39}R^{40}-$, $-O-$, $-S-$ and $-NR^{41}-$ radicals, R^{39} and R^{40} independently representing each time that they occur a hydrogen atom or an alkyl radical, and R^{41} representing a hydrogen atom or an alkyl radical; and

W represents O or S;

and the pharmaceutically acceptable salts of compounds of general formula **(I)** defined above

as Cdc25 phosphatase inhibitors, and in particular Cdc25-C phosphatase inhibitors, and/or CD45 phosphatase inhibitors. Said compounds can therefore be used for
5 preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase, and/or the CD45 phosphatase.

By alkyl, unless otherwise specified, is meant a linear or branched alkyl radical containing 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms and more preferentially 1 to 8 carbon atoms (and in particular 1 to 6 carbon atoms). By cycloalkyl,
10 unless otherwise specified, is meant a cycloalkyl radical containing 3 to 7 carbon atoms. By carbocyclic or heterocyclic aryl, is meant a carbocyclic or heterocyclic system with 1 to 3 condensed rings comprising at least one aromatic ring, a system being called heterocyclic when at least one of the rings which compose it comprises a heteroatom (O, N or S); when a carbocyclic or heterocyclic aryl radical is called substituted without
15 further specification, it means that said carbocyclic or heterocyclic aryl radical is substituted 1 to 3 times, and preferably 1 to 2 times by radicals different from a hydrogen atom which, unless otherwise specified, are chosen from a halogen atom and the alkyl or alkoxy radicals; moreover, unless otherwise specified, by aryl is meant exclusively a carbocyclic aryl. By haloalkyl, is meant an alkyl radical at least one of the
20 hydrogen atoms of which (and optionally all) is replaced by a halogen atom.

By cycloalkylalkyl, alkoxy, haloalkyl, haloalkoxy and aralkyl radicals, is meant respectively the cycloalkylalkyl, alkoxy, haloalkyl, haloalkoxy and aralkyl radicals, the alkyl, cycloalkyl and aryl radicals of which have the meanings indicated previously.

When it is indicated that a radical is optionally substituted 1 to 3 times, it is preferably
25 optionally substituted 1 to 2 times and more preferentially optionally substituted once.

By linear or branched alkyl having 1 to 6 carbon atoms, is meant in particular the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl, pentyl, neopentyl, isopentyl, hexyl, isohexyl radicals. By haloalkyl, is meant in particular the trifluoromethyl radical. By haloalkoxy, is meant in particular the trifluoromethoxy
30 radical. By carbocyclic aryl, is meant in particular the phenyl and naphthyl radicals. By aralkyl, is meant in particular the phenylalkyl radicals, and in particular the benzyl radical. By saturated carbon-containing cyclic system containing 1 to 3 condensed rings chosen independently from rings with 3 to 7 members, is meant in particular the cyclopropyl, cyclobutyl, cyclohexyl and adamantyl radicals. By heterocyclic or


heteroaryl aryl, is meant in particular the thienyl, furanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl and pyridyl radicals. Finally, by halogen, is meant fluorine, chlorine, bromine or iodine atoms.

By pharmaceutically acceptable salt, is meant in particular addition salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, pamoate and stearate. Also within the scope of the present invention, when they can be used, are the salts formed from bases such as sodium or potassium hydroxide. For other examples of pharmaceutically acceptable salts, reference can be made to "Salt selection for basic drugs", *Int. J. Pharm.* (1986), **33**, 201-217.

In certain cases, the compounds according to the present invention can comprise asymmetrical carbon atoms. As a result, the compounds according to the present invention have two possible enantiomeric forms, i.e. the "R" and "S" configurations. The present invention includes the two enantiomeric forms and all combinations of these forms, including the "RS" racemic mixtures. In an effort to simplify matters, when no specific configuration is indicated in the structural formulae, it should be understood that the two enantiomeric forms and their mixtures are represented.

Four variants of the compounds of general formula (I) can be distinguished:

- according to a first variant, the compounds of general formula (I) also correspond to general sub-formula (I)₁




(I)₁

in which W represents S and R¹, R², R³ and R⁴ have the same meaning as in general formula (I);


- according to a second variant, the compounds of general formula (I) also correspond to general sub-formula (I)₂

- 12 -

(I)₂


in which W represents O and R¹, R², R³ and R⁴ have the same meaning as in general formula (I);

- according to a third variant, the compounds of general formula (I) also correspond to general sub-formula (I)₃

(I)₃

5 in which W represents S and R¹, R², R³ and R⁴ have the same meaning as in general formula (I); and

- according to a fourth variant, the compounds of general formula (I) also correspond to general sub-formula (I)₄

(I)₄

10 in which W represents O and R¹, R², R³ and R⁴ have the same meaning as in general formula (I).

The compounds of general formula (I)₁ or (I)₂, or their pharmaceutically acceptable salts can therefore be used for preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase, and/or the CD45 phosphatase. Similarly, the compounds of general formula (I)₃ or (I)₄, or their pharmaceutically acceptable salts, can be used for preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase, and/or the CD45 phosphatase.

Preferably, the compounds of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄ used for preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase, include at least one of the following characteristics:

- R¹ representing an alkyl, cycloalkyl, alkoxyalkyl, -(CH₂)-X-Y, -(CH₂)-Z-NR⁵R⁶ or -CHR³⁵R³⁶ radical;
- R² representing a hydrogen atom or the methyl, ethyl or benzyl radical;
- R¹ and R² forming together with the nitrogen atom a heterocycle with 4 to 8 members (preferably 5 to 7 members, and in particular 6 members) comprising 1 to 2 heteroatoms (and preferably 2 heteroatoms), the members necessary to complete the heterocycle being chosen independently from the -CH₂-, -O- and -NR¹⁷ radicals (and preferably from the -CH₂- and -NR¹⁷- radicals), R¹⁷ representing a methyl or benzyl radical;
- R³ representing a hydrogen atom, a halogen atom or an alkyl, alkoxy or alkylthio radical;
- R⁴ representing an alkyl, -CH₂-COOR¹⁸ or -CH₂-CO-NR¹⁹R²⁰ or -CH₂-NR²¹R²² radical or also a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 4 times (and in particular 1 to 3 times) by substituents chosen independently from a halogen atom and an alkyl, haloalkyl, alkoxy or NR³⁷R³⁸ radical.

Generally, for use for preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase, the compounds of general formula (I) in which W represents a sulphur atom are preferred. Another useful alternative for use for preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase, will nevertheless be the use of the compounds of general formula (I) in which W represents an oxygen atom.

Moreover, the X radical will preferably represent a bond or a linear alkylene radical containing 1 to 5 carbon atoms. Preferably also, the Y radical will represent a saturated carbon-containing cyclic system containing 1 to 3 condensed rings chosen independently from rings with 3 to 7 members, or Y will represent a carbocyclic aryl radical optionally substituted (preferably optionally substituted by 1 to 3 radicals chosen from a halogen atom and an alkyl, haloalkyl, alkoxy, haloalkoxy, SO₂NHR⁹ or NR¹⁰R¹¹ radical, and more preferentially optionally substituted by 1 to 3 radicals chosen from a halogen atom and an alkyl, alkoxy, SO₂NHR⁹ or NR¹⁰R¹¹ radical) or also Y will represent an optionally substituted heterocyclic aryl radical, said heterocyclic aryl radical being preferably chosen from the aryl radicals with 5 members (and in particular from the imidazolyl, thienyl or pyridinyl radicals) and preferably optionally substituted by 1 to 3 radicals chosen from a halogen atom and an alkyl, haloalkyl, alkoxy, haloalkoxy, SO₂NHR⁹ or NR¹⁰R¹¹ radical, and more preferentially optionally substituted by 1 to 3 radicals chosen from a halogen atom and an alkyl, alkoxy, SO₂NHR⁹ or NR¹⁰R¹¹ radical; R⁹ will preferably represent a hydrogen atom and R¹⁰ and R¹¹ will preferably represent radicals chosen independently from the alkyl radicals. The Z radical will preferably represent an alkylene radical containing 1 to 5 carbon atoms, and in particular a -(CH₂)_p- radical in which p represents an integer from 1 to 3 (p being preferably equal to 1 or 2 and more preferentially equal to 1). Preferably also, R⁵ and R⁶ are chosen independently from a hydrogen atom and an alkyl radical, or also R⁵ and R⁶ will form together with the nitrogen atom which carries them a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, said heterocycle then being preferably one of the azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl and thiomorpholinyl radicals optionally substituted by 1 to 3 alkyl radicals (and preferably by 1 to 3 methyl radicals); still more preferentially, R⁵ and R⁶ are chosen independently from alkyl or alkoxycarbonyl radicals (and in particular R⁵ and R⁶ are each a methyl radical or *tert*-butoxycarbonyl) or R⁵ and R⁶ will form together with the nitrogen atom which carries them a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, said heterocycle being then preferably one of the azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl and thiomorpholinyl radicals optionally substituted by 1 to 3 alkyl radicals (and preferably by 1 to 3 methyl radicals). R¹⁸ will preferably represent a hydrogen atom or the methyl or ethyl radical.

Moreover, the R⁷, R¹², R¹³, R¹⁵, R¹⁶, R²⁶, R²⁷, R³⁹ and R⁴⁰ radicals are preferably chosen independently from a hydrogen atom and a methyl radical and the R⁸, R¹⁴, R¹⁷, R²⁸ and R⁴¹ radicals are preferably chosen independently from a hydrogen atom and a methyl or benzyl radical.

Moreover, with respect to R^{19} and R^{20} , the cases will be preferred in which R^{19} represents a hydrogen atom, an alkyl radical or a benzyl radical and R^{20} represents a hydrogen atom or the methyl radical, as well as those in which R^{19} and R^{20} form together with the nitrogen atom which carries them a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, said heterocycle then being preferably one of the azetidiny, pyrrolidiny, piperidiny, piperaziny, homopiperaziny, morpholiny and thiomorpholiny radicals optionally substituted by 1 to 3 alkyl radicals (and preferably optionally substituted by 1 to 3 methyl radicals).

Moreover, with respect to R^{21} and R^{22} , the cases will be preferred in which R^{21} represents a hydrogen atom, an alkyl radical or a benzyl radical and R^{22} represents a hydrogen atom or the methyl radical, as well as those in which R^{21} and R^{22} form together with the nitrogen atom which carries them a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, said heterocycle then being preferably one of the optionally substituted azetidiny, pyrrolidiny, piperidiny, piperaziny, homopiperaziny, morpholiny and thiomorpholiny radicals. With respect to the corresponding R^{32} , R^{33} and R^{34} radicals, these are preferably such that R^{32} and R^{33} are chosen independently from a hydrogen atom and an alkyl radical and preferably from a hydrogen atom and a methyl radical (R^{32} and R^{33} both representing still more preferentially hydrogen atoms) and that R^{34} represents a hydrogen atom, an alkyl radical or a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical (R^{34} representing still more preferentially a hydrogen atom or a methyl or phenyl radical).

Moreover, with respect to R^{35} and R^{36} , the cases will be preferred in which R^{35} and R^{36} form together with the carbon atom which carries them an indanyl radical or R^{35} and R^{36} form together with the carbon atom which carries them a saturated heterocycle containing 5 to 7 members and 1 to 2 heteroatoms chosen from O, N and S, the nitrogen atoms of said heterocycle being optionally substituted by radicals chosen from the alkyl radicals and the benzyl radical.

Moreover, with respect to R^{37} and R^{38} , the cases will be preferred in which R^{37} and R^{38} represent independently radicals chosen from the alkyl radicals.

Finally, when R^4 is a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 4 times, it is preferable that it is chosen from the group consisting of carbocyclic and heterocyclic aryl radicals optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl, alkoxy, haloalkoxy or

NR³⁷R³⁸ radical (and in particular 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl, alkoxy or haloalkoxy radical) and the 2,3,4,5-tetrafluorophenyl radical. More preferentially, when R⁴ is a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 4 times, R⁴ is chosen from the group consisting of carbocyclic and heterocyclic aryl radicals optionally substituted 1 to 2 times by substituents chosen independently from a halogen atom, an alkyl, haloalkyl, alkoxy, haloalkoxy or NR³⁷R³⁸ radical (and in particular 1 to 2 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl, alkoxy or haloalkoxy radical), a 3,4,5-trihalophenyl radical and the 2,3,4,5-tetrafluorophenyl radical.

More preferentially, the compounds of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄ used for preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase, include at least one of the following characteristics:

- R¹ representing an alkyl, cycloalkyl, or -(CH₂)-Z-NR⁵R⁶ radical;
- R² representing a hydrogen atom or the methyl radical;
- R³ representing a hydrogen atom, a halogen atom or the methoxy radical;
- R⁴ representing an alkyl, -CH₂-NR²¹R²² radical, or also a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 4 times (and in particular 1 to 3 times) by substituents chosen independently from a halogen atom and an alkyl, or NR³⁷R³⁸ radical.

Also more preferentially, the compounds of general formula (I), (I)', (I)", (I)₁, (I)₂, (I)₃ or (I)₄ used according to the invention include at least one of the following characteristics:

- R¹ representing a -(CH₂)-Z-NR⁵R⁶ radical;
- R² representing a hydrogen atom;
- R³ representing a hydrogen atom or a halogen atom (said halogen atom being preferably a chlorine or bromine atom);
- R⁴ representing an alkyl radical or also a phenyl, pyridyl, thienyl or furanyl radical optionally substituted by 1 to 4 (preferably 1 to 3) halogen atoms or by an NR³⁷R³⁸ radical.

In still more particularly preferred fashion, the compounds of general formula **(I)**, **(I)₁**, **(I)₂**, **(I)₃** or **(I)₄** used for preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase, include at least one of the following characteristics:

- 5 • R³ representing a hydrogen atom or a chlorine atom (and more preferentially a hydrogen atom);
- R⁴ representing an alkyl radical or also a phenyl, pyridyl, thienyl or furanyl radical optionally substituted by 1 to 4 (preferably 1 to 3) halogen atoms (and in particular R⁴ representing an alkyl radical, and preferably an alkyl radical containing 1 to 4
10 carbon atoms, and more preferentially also a methyl or ethyl radical).

According to a particular variant of the invention, W represents O. In this particular case, it is preferable that R¹ represents an aryl radical, and in particular a phenyl radical, optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl or alkoxy radical. More preferentially, whenever W
15 represents O, it is preferable that R¹ represents a phenyl radical optionally substituted by a halogen atom (said halogen atom being preferably a fluorine atom).

According to a particular aspect of the invention, R⁴ will represent a phenyl radical or a heterocyclic aryl radical with 5 to 6 members optionally substituted 1 to 4 times (and preferably 1 to 3 times) by substituents chosen from the group consisting of halogen
20 atoms, the trifluoromethyl radical and the trifluoromethoxy radical (and preferably chosen from the group consisting of halogen atoms and the trifluoromethyl radical). In particular, said heterocyclic aryl with optionally substituted 5 to 6 members is an optionally substituted pyridine, thiophene, furan or pyrrole ring.

According to another particular aspect, compounds of general formula **(I)** in which W
25 represents S, R³ represents a hydrogen atom, the substituent -NR¹R² (the preferences indicated previously for R¹ and R² remaining applicable) is attached at position 5 of the benzothiazolodione ring and R⁴ is chosen from the alkyl, cycloalkylalkyl, -CH₂-COOR¹⁸, -CH₂-CO-NR¹⁹R²⁰ and -CH₂-NR²¹R²² radicals (R⁴ being preferably alkyl or cycloalkylalkyl and more preferentially alkyl according to this particular aspect of the
30 invention) are used for preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase.

Preferably, the compounds of general formula **(I)**, **(I)₁**, **(I)₂**, **(I)₃** or **(I)₄** or their pharmaceutically acceptable salts are used for preparing a medicament intended to treat

a disease chosen from the following diseases / the following disorders: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, neurodegenerative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia, auto-immune diseases, transplant rejections, inflammatory diseases and allergies.

Quite particularly, the compounds of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄ or their pharmaceutically acceptable salts can be used for preparing a medicament intended to treat cancer, and in particular breast cancer, lymphomas, cancers of the neck and head, lung cancer, cancer of the colon, prostate cancer and cancer of the pancreas.

According to a particular variant, the compounds of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄ or their pharmaceutically acceptable salts can be used for preparing a medicament intended to treat spontaneous alopecia, alopecia induced by exogenous products or radiation-induced alopecia.

The compounds of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄ can also be used in a method of treatment for tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, neurodegenerative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia, auto-immune diseases, transplant rejections, inflammatory diseases and allergies, said method comprising the administration of a therapeutically effective dose of a compound of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄ to the patient requiring this treatment.

The pharmaceutical compositions containing a compound of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄, can be presented in the form of solids, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories. Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone and wax.


The pharmaceutical compositions containing a compound of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄, can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups. Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or the glycols, as well as their mixtures, in varying proportions, in water.

The administration of a medicament according to the invention can be carried out by topical, oral, parenteral route, by intramuscular injection, etc.

5 The administration dose envisaged for a compound of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄, is comprised between 0.1 mg to 10 g depending on the type of active compound used.

Advantageously, the compounds of general formula (I), (I)₁, (I)₂, (I)₃ or (I)₄ can be prepared according to a selective preparation process. Said process makes it possible to substitute either position 5 or position 6 of the benzothiazole-4,7-dione or benzooxazole-4,7-dione nucleus and therefore to obtain a compound of general formula (I)₁ and not the corresponding compound of general formula (I)₃ (or *vice versa*), or also
10 a compound of general formula (I)₂ and not the corresponding compound of general formula (I)₄ (or *vice versa*).

The invention therefore relates firstly to a process for the preparation of a compound of general formula (I)₁ or (I)₂ as defined previously in which R³ represents a hydrogen atom, said process being characterized in that the compound of general formula (A)
15




(A)

in which W represents a sulphur atom or an oxygen atom and R⁴ has the same meaning as in general formula (I)₁ or (I)₂ is reacted with an amine of general formula R¹R²NH in a protic solvent at a temperature preferably comprised between 20°C and the boiling temperature of the solvent.

20 Preferably, the protic solvent for the abovementioned process is chosen from ethanol and methanol.

The invention relates in particular to a process for the preparation of a compound of general formula (I)₃ or (I)₄ as defined previously in which R³ represents a hydrogen atom, said process being characterized in that the compound of general formula (K)

- 20 -



(K)

in which W represents a sulphur atom or an oxygen atom and R^4 has the same meaning as in general formula (I)₃ or (I)₄ is reacted with an amine of general formula R^1R^2NH in a protic solvent at a temperature preferably comprised between 20°C and the boiling temperature of the solvent.

- 5 Preferably, the protic solvent for the abovementioned process is chosen from ethanol and methanol.

The invention also relates, as novel products, to the compounds of general formula (A) in which W and R^4 have the meaning indicated previously, it being understood however that if W represents a sulphur atom then R^4 is not methyl, as well as the salts of the latter.

The invention thus relates in particular, as novel products, to the compounds of general formula (A) in which W represents an oxygen atom (hereafter respectively the compounds of general formula (A')), as well as the salts of the latter.

- 15 It similarly relates to the compounds of general formula (A) in which W represents a sulphur atom and R^4 has the meaning indicated previously but does not represent methyl (hereafter respectively the compounds of general formula (A'')), as well as the salts of the latter. Preferably, the compounds of general formula (A'') or their salts are such that R^4 has the meaning indicated previously but does not represent alkyl.

- 20 The invention also relates, as novel products, to the compounds of general formula (K) in which W and R^4 have the meaning indicated previously, it being understood however that if W represents a sulphur atom then R^4 is not the phenyl group (but can be a substituted phenyl group), as well as the salts of the latter.

- 25 The invention therefore in particular relates, as novel products, to the compounds of general formula (K) in which W represents an oxygen atom (hereafter respectively the compounds of general formulae (K')), as well as the salts of the latter.

It relates similarly to the compounds of general formula (K) in which W represents a sulphur atom and R⁴ has the meaning indicated previously but does not represent the phenyl group (but can be a substituted phenyl group), compounds hereafter called the compounds of general formula (K''), as well as the salts of the latter. Preferably, the compounds of general formula (K'') or their salts are such that R⁴ represents a phenyl group substituted by at least one halogen atom or also such that R⁴ represents an alkyl radical.

The invention also relates to the compounds of general formula (I) chosen from the following compounds:

- 10 - 2-(2-chloro-6-fluorophenyl)-5-{{2-(dimethylamino)ethyl}amino}-1,3-benzothiazole-4,7-dione;
- 2-(2-chloro-6-fluorophenyl)-5-[(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazole-4,7-dione;

as well as the salts of the latter;

- 15 The invention also relates, as medicaments, to said compounds or their pharmaceutically acceptable salts. It relates moreover to the pharmaceutical compositions comprising, as active ingredient, one of said compounds or a pharmaceutically acceptable salt of the latter, as well as at least one pharmaceutically acceptable excipient.
- 20 A subject of the invention is also the use of said compounds or their pharmaceutically acceptable salts for preparing a medicament intended to inhibit the Cdc25 phosphatases, and in particular the Cdc25-C phosphatase, and/or the CD45 phosphatase. Preferably, said compounds or their pharmaceutically acceptable salts are used for preparing a medicament intended to treat a disease chosen from the following diseases / the
- 25 following disorders: tumorous proliferative diseases, and in particular cancer, non-tumorous proliferative diseases, neurodegenerative diseases, parasitic diseases, viral infections, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia, auto-immune diseases, transplant rejections, inflammatory diseases and allergies. Quite particularly, said compounds or their pharmaceutically acceptable
- 30 salts can be used for preparing a medicament intended to treat cancer, and in particular breast cancer, lymphomas, cancers of the neck and head, lung cancer, cancer of the colon, prostate cancer and cancer of the pancreas.

The compounds of general formula (I) can be prepared by the processes described hereafter.

Preparation of the compounds of general formula (I)

- 5 The preparation processes hereafter are given by way of illustration and a person skilled in the art can subject them to the variations that he deems useful, both with respect to the reagents and to the reaction conditions and techniques.

According to the present invention, the processes hereafter can be used in order to obtain exclusively a compound of general formula (I)₁ and not the corresponding
 10 compound of general formula (I)₃ (or *vice versa*), or also a compound of general formula (I)₂ and not the corresponding compound of general formula (I)₄ (or *vice versa*).

A) Process for the preparation of the regioisomers of general formula (I)₁ or (I)₂

- Generally, the compounds of general formula (I)₁ or (I)₂ in which R³ represents H can
 15 be prepared according to the method illustrated in Diagram 1 hereafter.




Diagram 1

- According to this method, the compounds of general formula (I)₁ or (I)₂, in which W, R¹, R² and R⁴ are as defined above and R³ represents H, are obtained by treatment of the
 20 compounds of general formula (A) with amines of general formula R¹R²NH in a protic solvent such as methanol or ethanol, at a temperature preferably comprised between 25°C and the boiling temperature of the solvent (Yasuyuki Kita et al., *J. Org. Chem.* (1996), **61**, 223-227).

In the case where it is also desired to substitute position 6 of the benzothiazolledione or benzoxazolledione nucleus (compounds of general formula (I)₁ or (I)₂ in which R³ ≠ H), it is sufficient to carry out an additional substitution using the conditions familiar to a person skilled in the art.

5 **i) W represents a sulphur atom:**

Preparation of the intermediates of general formula (A)

When W represents a sulphur atom, the intermediates of general formula (A) can be prepared according to the process represented in Diagram 2 hereafter.




Diagram 2

10 The compounds of general formula (A) in which R⁴ is as defined above can be obtained by oxidative demethylation of the compounds of general formula (B), for example by treatment with chromium oxide (VI) in acetic acid (J. M. de L. Vanderlei et al., *Tetrahedron: Asymmetry* (1997), 8 (16), 2781-2785), or by treatment with a 50% hydrogen peroxide solution in the presence of phosphomolybdic acid and formic acid (A. S. Chida et al., *Synth Commun* (2001), 5, 657-660), or also by treatment with dichlorodicyanoquinone (DDQ) in an H₂O/THF mixture (K. Narayanan, *Heterocycles* (1991), 10, 2005-2014) or also by treatment with cerium ammonium nitrate in an equimolar acetonitrile / water or ethyl acetate / water mixture under vigorous stirring at ambient temperature.

20 The nitrated compound of general formula (B.i) can be obtained by treatment of the compound of general formula (B) with cerium ammonium nitrate (CAN). The compound of general formula (A) can then be obtained after reduction of the nitro group by the action of hydrogen in the presence of palladium on carbon or by the action

of tin chloride in order to obtain the intermediate of general formula **(B.ii)** which is then oxidized in order to finally produce the quinone of general formula **(A)** by the action of cerium ammonium nitrate (cf. Diagram 3 hereafter; K. Mohri et al., *Chem Pharm Bull*, (1998), **12**, 1872-1877).




Diagram 3

5 *Preparation of the intermediates of general formula (B)*

The compounds of general formula **(B)**, in which R⁴ is as defined above, can be obtained in 3 stages (M. A. Lyon et al., *J. Chem. Soc., Perkin Trans 1*, (1999), 437-442) from 3,5-dimethoxyaniline converted successively to amide **(D)** by the action of the corresponding acid chloride according to standard methods known to a person skilled in the art. The amides of general formula **(D)** are then converted to thioamides of general formula **(C)** by treatment with Lawesson's reagent in dry toluene at a temperature preferably comprised between 80°C and reflux for a duration preferably comprised between 2 hours and 18 hours, or by potassium pentasulphide in DME at a temperature preferably comprised between 85°C and reflux. The thioamides of general formula **(C)** are then treated with potassium ferricyanide in aqueous medium in the presence of soda according to the method of Jacobson (P. Jacobson, *Chem. Ber.* (1886), **19**, 1067) in order to produce the compounds of general formula **(B)**.

ii) W represents an oxygen atom:

Preparation of the intermediates of general formula (A)

When W represents an oxygen atom, the intermediates of general formula (A) can be prepared according to the process represented in Diagram 4 below.





Diagram 4


- The compounds of general formula (A), in which R⁴ is as defined above, can be obtained in 3 stages from 4-methoxy-2,6-dinitrophenol (described in particular by P. Cotelle and J.-P. Catteau, *Synth. Commun.*, **26**, (1996), 4105-4112), which, once esterified in order to produce the intermediate of general formula (F) according to the usual methods known to a person skilled in the art can be subjected to the action of a reducing agent under dehydrating conditions (such as, for example, tin and hydrogen chloride in ethanol described by Y.A.M. Marghlani et al. *Pakistan J. Sci. Ind. Res.*, **23**, (1980), 166-168) in order to provide a 7-amino-5-methoxy-benzoxazole derivative of general formula (E). The 7-amino function of the compound of general formula (E) then allows its oxidation to be achieved in order to produce the compound of general formula (A) according to processes described previously.
- It is also possible to envisage the preparation of intermediates of general formula (A) in which W represents an oxygen atom according to the process described in Diagram 4a hereafter.

**Diagram 4a**

According to the alternative synthesis presented in Diagram 4a, 4-methoxy-2-nitrophenol (commercial) is converted to 5-methoxy-benzoxazole derivative of general formula (H), either by dehydrating esterification/reduction of Diagram 4, or by reduction followed by condensation described previously. The intermediate of general formula (H) is then nitrated and reduced to the corresponding amine according to a method already described above (cf. Diagram 3), then oxidized as previously to the quinone of general formula (A).

10 **B) Process for the preparation of the regioisomers of general formula (I)₃ or (I)₄**

Generally, the compounds of general formula (I)₃ or (I)₄ in which R³ represents H can be prepared according to the method illustrated in Diagram 5 hereafter.

**Diagram 5**


According to this method, the compounds of general formula (I)₃ or (I)₄, in which W, R¹, R² and R⁴ are as defined above and R³ represents H, are obtained by treatment of the compounds of general formula (K) with amines of general formula R¹R²NH in a protic solvent such as methanol or ethanol, at a temperature preferably comprised between 25°C and the boiling temperature of the solvent (Yasuyuki Kita et al., *J. Org. Chem.* (1996), **61**, 223-227).

In the case where it is also desired to substitute position 6 of the benzothiazole-dione or benzoxazole-dione nucleus (compounds of general formula (I)₃ or (I)₄ in which R³ ≠ H), it is sufficient to carry out an additional substitution using conditions familiar to a person skilled in the art.

i) W represents a sulphur atom:

Preparation of the intermediates of general formula (K)

When W represents a sulphur atom, the intermediates of general formula (K) can be prepared according to the process represented in Diagram 6 hereafter.

**Diagram 6**

The compounds of general formula **(K)** in which R^4 is as defined above can be obtained according to a process analogous to that described for the preparation of the intermediates of general formula **(A)** (cf. Diagrams 2 and 3), the starting product being 2,4-dimethoxyaniline (commercial).

5 **ii) W represents an oxygen atom:**

Preparation of the intermediates of general formula (K)

When W represents an oxygen atom, the intermediates of general formula **(K)** can be prepared according to the process represented in Diagram 7 hereafter.

10

Diagram 7

The methods presented in Diagram 7 are analogous to those presented in Diagram 4, but this time the starting product is 5-methoxy-2-nitro-resorcinol (described in particular by J.F. Grove et al. *J. Chem. Soc.* (1956), 1956-1963).

Alternatively, the method represented in Diagram 8 hereafter can also be used.

15




Diagram 8

According to this method, (commercial) 5-methoxy-2-nitrophenol is converted to 6-methoxy-benzoxazole derivative of general formula (S), either using a dehydrating esterification/reduction reaction as presented in Diagram 4, or by reduction followed by condensation described previously. The intermediate of general formula (S) is then
5 nitrated and reduced to the corresponding amine of general formula (R) according to the process presented in Diagram 3, then oxidized as previously to the quinone of general formula (K).

As regards the temperatures referred to in the present text, the term "approximately XX°C" indicates that the temperature in question corresponds to a range of more or less
10 10°C, either side of the temperature XX°C, and preferably to a range of more or less 5°C, either side of the temperature XX°C.

Unless otherwise specified, all the technical and scientific terms used here have the same meaning as that usually understood by an ordinary specialist in the field to which this invention belongs. Similarly, all the publications, patent applications, all the patents
15 and all other references mentioned here are incorporated by way of reference.

The following examples are presented in order to illustrate the above procedures and should in no event be considered as a limit to the scope of the invention.

EXAMPLES

Method used for measuring the retention time (r.t.) and the molecular peak (MH+)

- 20 The compounds are characterized by their retention time (r.t.), expressed in minutes, determined by liquid chromatography (LC), and their molecular peak (MH+) determined by mass spectrometry (MS), a single quadripole mass spectrometer (Micromass, Platform model) equipped with an electrospray source is used with a resolution of 0.8 Da at 50% valley.
- 25 For the examples below, the elution conditions corresponding to the results indicated are the following: transition of an acetonitrile-water-trifluoroacetic acid mixture 50-950-0.2 (A) to an acetonitrile-water mixture 950-50 (B) via a linear gradient over a period of 8.5 minutes, then elution with the pure mixture B for 10.5 minutes.

Example 1: 2-(2,6-difluorophenyl)-5-{[2-(dimethylamino)ethyl]amino}-1,3-benzothiazole-4,7-dione:

1.1) *N*-(3,5-dimethoxyphenyl)-2,6-difluorobenzamide:

- 5 5.5 ml (39.2 mmol; 1.2 equivalent) of triethylamine and 4.5 ml (35.9 mmol; 1.1 equivalent) of 2,6-difluorobenzoyl chloride are added to 5 g (32.6 mmol) of 3,5-dimethoxyaniline in solution in 100 ml of anhydrous toluene. The reaction medium is maintained under stirring at 70°C for 1 hour 30 minutes, then, after returning to ambient temperature, washed with 3 times 50 ml of water. The resulting organic phase is dried
10 over magnesium sulphate then the solvent is evaporated off under reduced pressure. The expected product is obtained in the form of a white powder (8.75 g; yield = 97 %) used in the following stage without other purification.

MS-LC: MH⁺ = 294.11; r.t. = 9.93 min.

1.2) *N*-(3,5-dimethoxyphenyl)-2,6-difluorobenzenecarbothioamide:

- 15 20.3 g (50 mmol; 1.5 equivalents) of Lawesson's reagent is added to 9.8 g (33.4 mmol) of *N*-(3,5-dimethoxyphenyl)-2,6-difluorobenzamide in solution in 150 ml of anhydrous toluene. The reaction medium is maintained under stirring at 120°C for 8 hours, then, after returning to ambient temperature, is washed with 3 times 75 ml of water. The resulting organic phase is dried over magnesium sulphate then the solvent is evaporated
20 off under reduced pressure. The residue is purified by chromatography on a silica column (eluent: dichloromethane/methanol 98/2) and the expected product is obtained in the form of a green oil (10 g; yield = 96 %).

MS-LC: MH⁺ = 310.06; r.t. = 10.53 min.

1.3) 2-(2,6-difluorophenyl)-5,7-dimethoxy-1,3-benzothiazole:

- 25 170 ml (103 mmol; 3 equivalents) of a freshly prepared 20% aqueous solution of potassium ferricyanide is added to 10.3 g (33.3 mmol) of *N*-(3,5-dimethoxyphenyl)-2,6-difluorobenzenecarbothioamide dissolved in 150 ml of a 1.5M soda solution. The reaction medium is maintained under stirring at ambient temperature for 24 hours, then the beige precipitate formed is filtered, washed with water and dried (6.8 g; yield =
30 66%). The mother liquors can be extracted by 3 times 75 ml of dichloromethane, then the organic phases are washed with a saturated solution of sodium chloride. After concentration under reduced pressure, the residue obtained can be purified on a silica

column (eluent: ethyl acetate/heptane: 1/3) in order to provide another 2 g of expected product (overall yield = 86%). Melting point: 136-138°C.

NMR ¹H (DMSO d₆, 400 MHz, δ): 7.65 (m, 1H, arom. H); 7.36-7.31 (m, 3H, arom. H); 6.75 (m, 1H, arom. H); 3.96 (s, 3H, CH₃); 3.87 (s, 3H, CH₃).

5 MS-LC: MH⁺ = 308.12; r.t. = 11.48 min.

1.4) 2-(2,6-difluorophenyl)-5-methoxy-1,3-benzothiazole-4,7-dione:

1.4.1) 2-(2,6-difluorophenyl)-5,7-dimethoxy-4-nitro-1,3-benzothiazole:

10 A solution of 16 g (29.3 mmol; 3 equivalents) of cerium ammonium nitrate in 40 ml of water is added dropwise to 3 g (9.76 mmol) of 2-(2,6-difluorophenyl)-5,7-dimethoxy-1,3-benzothiazole in solution in 75 ml of ethyl acetate. The reaction mixture is maintained under stirring for 2 hours at ambient temperature, then washed with 3 times 20 ml of water. The organic phases are dried over magnesium sulphate, filtered then concentrated under reduced pressure. The residue is purified by chromatography on a silica column (eluent: ethyl acetate/heptane: 3/7). Two fractions are separated:

15 0.3 g (yield = 10%) of 2-(2,6-difluorophenyl)-5-methoxy-1,3-benzothiazole-4,7-dione is obtained in the form of yellow powder.

MS-LC: MH⁺ = 308.08; r.t. = 10 min.

1.5 g of 2-(2,6-difluorophenyl)-5,7-dimethoxy-4-nitro-1,3-benzothiazole (45% yield) is obtained in the form of orange-coloured powder.

20 NMR ¹H (DMSO d₆, 400 MHz, δ): 7.72 (m, 1H, arom. H); 7.38 (m, 2H, arom. H); 7.11 (m, 1H, arom. H); 4.12 (s, 3H, CH₃); 4.07 (s, 3H, CH₃).

MS-LC: MH⁺ = 353.05; r.t. = 11.30 min.

1.4.2) 2-(2,6-difluorophenyl)-5,7-dimethoxy-1,3-benzothiazol-4-amine:

25 230 mg (0.65 mmol) of intermediate 1.4.1 dissolved in 15 ml of concentrated hydrochloric acid is reacted with 0.5 g (2.2 mmol; 3.4 equivalents) of dihydrated tin chloride in 5 ml of water. The reaction mixture is maintained under stirring for 2 hours at 50°C, then after returning to ambient temperature, poured on ice before being neutralized with a 5M soda solution. The product is then extracted with 3 times 15 ml of dichloromethane, the organic phases are combined, washed with a saturated solution of sodium chloride, dried over magnesium sulphate, filtered, then, after concentration
30 under reduced pressure, the expected product is obtained in the form of a yellow oil. It is used in the following stage without other purification.

NMR ¹H (DMSO d₆, 400 MHz, δ): 7.67 (m, 1H, arom. H); 7.34 (m, 2H, arom. H); 6.92 (s, 1H, arom. H); 3.91 (s, 3H, CH₃); 3.90 (s, 3H, CH₃).

MS-LC: MH⁺ = 323.10; r.t. = 9.86 min.

1.4.3) 2-(2,6-difluorophenyl)-5-methoxy-1,3-benzothiazole-4,7-dione:

- 5 A solution of 1.22 g of cerium ammonium nitrate (2.23 mmol, 2.1 equivalents) in 8 ml of water is added to 343 mg (1.06 mmol) of 2-(2,6-difluorophenyl)-5,7-dimethoxy-1,3-benzothiazol-4-amine in solution in 25 ml of ethyl acetate. The reaction mixture is maintained under vigorous stirring at ambient temperature for 1 hour 30 minutes then the organic phase is separated and washed with 3 times 20 ml of water, then dried over
- 10 magnesium sulphate, filtered and the solvent is evaporated off under reduced pressure. The residue is purified by chromatography on a silica column (eluent: ethyl acetate/heptane: 3/7) and 280 mg (yield = 86%) of 2-(2,6-difluorophenyl)-5-methoxy-1,3-benzothiazole-4,7-dione is obtained in the form of yellow powder.

NMR ¹H (DMSO d₆, 400 MHz, δ): 7.72 (m, 1H, arom. H); 7.39 (m, 2H, arom. H); 6.32 (s, 1H, CH); 3.88 (s, 3H, CH₃).

MS-LC: MH⁺ = 308.05; r.t. = 9.99 min.

1.5) 2-(2,6-difluorophenyl)-5-{[2-(dimethylamino)ethyl]amino}-1,3-benzothiazole-4,7-dione:

- 104 ml (0.95 mmol; 1.5 equivalents) of N,N-dimethylethylenediamine is added to 195
- 20 mg of 2-(2,6-difluorophenyl)-5-methoxy-1,3-benzothiazole-4,7-dione in solution in 20 ml of anhydrous ethanol. The reaction mixture is stirred at 70°C for 2 hours then the solvent is evaporated off under reduced pressure. The residue is purified on a silica column (eluent: 5% methanol in dichloromethane). 130 mg (yield = 57%) of expected compound is obtained in the form of a red powder.

25 NMR ¹H (DMSO d₆, 400 MHz, δ): 7.72 (m, 1H, arom. H); 7.52 (m, 1H, NH.); 7.38 (m, 2H, arom. H); 5.60 (s, 1H, CH); 3.28 (m, 2H, CH₂); 2.53 (m, 2H, CH₂); 2.20 (s, 6H, 2CH₃).

MS-LC: MH⁺ = 364.14; r.t. = 7.85 min.

- 30 *The compounds of Examples 2 to 7 are obtained in a similar manner to that described for Example 1, with appropriate acyl chlorides replacing 2,6-difluorobenzoyl chloride in the first stage and N-(2-aminoethyl)pyrrolidine replacing N,N-dimethylethylenediamine in the last stage for Examples 3, 5 and 7.*

Example 2: 2-(2,5-dichlorothien-3-yl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione:

2.1) 2,5-dichloro-N-(3,5-dimethoxyphenyl)thiophene-3-carboxamide:

5 NMR ¹H (DMSO d₆, 400 MHz, δ): 10.20 (s, 1H, NH); 7.47 (s, 1H, arom. H); 6.95 (s, 1H, arom. H); 6.27 (s, 1H, arom. H); 3.72 (s, 6H, 2CH₃).
MS-LC: MH⁺ = 332.01; r.t. = 11.08 min.

2.2) 2,5-dichloro-N-(3,5-dimethoxyphenyl)thiophene-3-carbothioamide:

10 NMR ¹H (DMSO d₆, 400 MHz, δ): 11.96 (s, 1H, NH); 7.30 (s, 1H, arom. H); 7.25 (s, 1H, arom. H); 6.44 (s, 1H, arom. H); 3.74 (s, 6H, 2CH₃).
MS-LC: MH⁺ = 348.00; r.t. = 11.55 min.

2.3) 2-(2,5-dichlorothien-3-yl)-5,7-dimethoxy-1,3-benzothiazole:

NMR ¹H (DMSO d₆, 400 MHz, δ): 7.72 (s, 1H, arom. H); 7.22 (s, 1H, arom. H); 6.73 (s, 1H, arom. H); 3.96 (s, 3H, CH₃); 3.86 (s, 3H, CH₃).
MS-LC: MH⁺ = 345.94; r.t. = 12.77 min.

15 *2.4) 2-(2,5-dichlorothien-3-yl)-5-methoxy-1,3-benzothiazole-4,7-dione:*

NMR ¹H (DMSO d₆, 400 MHz, δ): 7.75 (s, 1H, arom. H); 6.31 (s, 1H, CH); 3.88 (s, 3H, CH₃).
MS-LC: MH⁺ = 345.98; r.t. = 11.52 min.

20 *2.5) 2-(2,5-dichlorothien-3-yl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione:*

NMR ¹H (DMSO d₆, 400 MHz, δ): 7.72 (s, 1H, arom. H); 7.51 (m, 1H, NH.); 5.58 (s, 1H, CH); 3.36 (m, 2H, CH₂); 2.54 (m, 2H, CH₂); 2.20 (s, 6H, 2CH₃).
MS-LC: MH⁺ = 402.06; r.t. = 8.42 min.

25 **Example 3: 2-(2,5-dichlorothien-3-yl)-5-[(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazole-4,7-dione:**

MS-LC: MH⁺ = 427.97; r.t. = 8.70 min.

Example 4: 5-[[2-(dimethylamino)ethyl]amino]-2-(4-fluorophenyl)-1,3-benzothiazole-4,7-dione:

4.1) *N*-(3,5-dimethoxyphenyl)-4-fluorobenzamide:

NMR ¹H (DMSO d₆, 400 MHz, δ): 10.15 (s, 1H, NH); 8.01 (m, 2H, arom. H); 7.36 (m, 2H, arom. H); 7.05 (m, 2H, arom. H); 6.26 (s, 1H, arom. H); 3.73 (s, 6H, 2CH₃).

5 MS-LC: MH⁺ = 276.17; r.t. = 10.07 min.

4.2) *N*-(3,5-dimethoxyphenyl)-4-fluorobenzenecarbothioamide:

MS-LC: MH⁺ = 292.17; r.t. = 10.72 min.

4.3) 2-(4-fluorophenyl)-5,7-dimethoxy-1,3-benzothiazole:

10 NMR ¹H (DMSO d₆, 400 MHz, δ): 8.11 (m, 2H, arom. H); 7.40 (m, 2H, arom. H); 7.22 (s, 1H, arom. H); 6.69 (s, 1H, arom. H); 3.95 (s, 3H, CH₃); 3.86 (s, 3H, CH₃).

MS-LC: MH⁺ = 290.07; r.t. = 11.93 min.

4.4) 2-(4-fluorophenyl)-5-methoxy-1,3-benzothiazole-4,7-dione:

NMR ¹H (DMSO d₆, 400 MHz, δ): 8.15 (m, 2H, arom. H); 7.42 (m, 2H, arom. H); 6.28 (s, 1H, CH); 3.87 (s, 3H, CH₃).

15 MS-LC: MH⁺ = 290.14; r.t. = 11.95 min.

4.5) 5-{[2-(dimethylamino)ethyl]amino}-2-(4-fluorophenyl)-1,3-benzothiazole-4,7-dione:

20 NMR ¹H (DMSO d₆, 400 MHz, δ): 8.11 (m, 2H, arom. H); 7.48 (m, 1H, NH); 7.41 (m, 2H, arom. H); 5.57 (s, 1H, CH); 3.26 (m, 2H, CH₂); 2.55 (m, 2H, CH₂); 2.22 (s, 6H, 2CH₃).

MS-LC: MH⁺ = 346.18; r.t. = 8.01 min.

Example 5: 2-(4-fluorophenyl)-5-[(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazole-4,7-dione:

25 NMR ¹H (DMSO d₆, 400 MHz, δ): 8.12 (m, 2H, arom. H); 7.58 (m, 1H, NH); 7.41 (m, 2H, arom. H); 5.55 (s, 1H, CH); 3.41 (m, 2H, CH₂); 2.69 (m, 2H, CH₂); 2.51 (m, 2H, CH₂); 2.44 (m, 2H, CH₂); 1.70 (m, 4H, 2CH₂).

MS-LC: MH⁺ = 372.19; r.t. = 8.12 min.

Example 6: 2-(2-chloro-6-fluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione:

6.1) 2-chloro-N-(3,5-dimethoxyphenyl)-6-fluorobenzamide:

5 NMR ¹H (DMSO d₆, 400 MHz, δ): 10.69 (s, 1H, NH); 7.53 (m, 1H, arom. H); 7.43 (m, 1H, arom. H); 7.37 (m, 1H, arom. H); 6.93 (m, 2H, arom. H); 6.29 (s, 1H, arom. H); 3.72 (s, 6H, 2CH₃).

MS-LC: MH⁺ = 310.15; r.t. = 10.11 min.

6.2) 2-chloro-N-(3,5-dimethoxyphenyl)-6-fluorobenzenecarbothioamide:

10 NMR ¹H (DMSO d₆, 400 MHz, δ): 7.41 (m, 2H, arom. H); 7.27 (m, 3H, arom. H); 6.46 (s, 1H, arom. H); 3.75 (s, 6H, 2CH₃).

MS-LC: MH⁺ = 326.09; r.t. = 10.73 min.

6.3) 2-(2-chloro-6-fluorophenyl)-5,7-dimethoxy-1,3-benzothiazole:

15 NMR ¹H (DMSO d₆, 400 MHz, δ): 7.66 (m, 1H, arom. H); 7.56 (m, 1H, arom. H); 7.47 (m, 1H, arom. H); 7.30 (s, 1H, arom. H); 6.77 (s, 1H, arom. H); 3.96 (s, 3H, CH₃); 3.88 (s, 3H, CH₃).

MS-LC: MH⁺ = 324.03; r.t. = 11.60 min.

6.4) 2-(2-chloro-6-fluorophenyl)-5-methoxy-1,3-benzothiazole-4,7-dione:

20 NMR ¹H (DMSO d₆, 400 MHz, δ): 7.69 (m, 1H, arom. H); 7.61 (m, 1H, arom. H); 7.52 (m, 1H, arom. H); 6.32 (s, 1H, CH); 3.88 (s, 3H, CH₃).

MS-LC: MH⁺ = 324.03; r.t. = 9.23 min.

6.5) 2-(2-chloro-6-fluorophenyl)-5-[[2-(dimethylamino)ethyl]amino]-1,3-benzothiazole-4,7-dione:

25 NMR ¹H (DMSO d₆, 400 MHz, δ): 7.67 (s, 1H, arom. H); 7.59 (m, 1H, arom. H); 7.55 (m, 1H, NH.); 7.49 (m, 1H, arom. H); 5.61 (s, 1H, CH); 3.36 (m, 2H, CH₂); 2.54 (m, 2H, CH₂); 2.19 (s, 6H, 2CH₃).

MS-LC: MH⁺ = 380.10; r.t. = 7.88 min.

Example 7: 2-(2-chloro-6-fluorophenyl)-5-[(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazole-4,7-dione:

MS-LC: MH⁺ = 406.10; r.t. = 8.01 min.

Pharmacological study of the compounds of the invention**Test protocols***i) Measurement of the phosphatase activity of the purified Cdc25C recombinant enzyme*

5 The phosphatase activity of the MBP-Cdc25C protein is evaluated by dephosphorylation of 3-O-methylfluorescein-phosphate (OMFP) to 3-O-methylfluorescein (OMF) with determination of the fluorescence of the reaction product at 475 nm. This test allows identification of the inhibitors of Cdc25 recombinant enzyme. The preparation of the fusion protein MBP-Cdc25C is described in PCT Patent Application WO 01/44467.

- 10 The reaction is carried out in 384-well plate format in a final volume of 50 μ l. The MBP-Cdc25C protein (prepared as described above) is stored in the following elution buffer: 20 mM Tris-HCl pH 7.4; 250 mM NaCl; 1mM EDTA; 1 mM of dithiothreitol (DTT); 10 mM maltose. It is diluted to a concentration of 60 μ M in the following reaction buffer: 50 mM Tris-HCl pH 8.2; 50 mM NaCl; 1 mM DTT; 20% glycerol.
- 15 Measurement of the background noise is carried out with the buffer without addition of the enzyme. The products are tested at decreasing concentrations starting from 40 μ M. The reaction is initiated by the addition of an OMFP solution at 500 μ M final (prepared extemporaneously from a 12.5 mM stock solution in 100% DMSO (Sigma #M2629)).
- 20 475 nm is read using a Victor² plate reader (EGG-Wallac). Determination of the 50% inhibitory concentration of the enzymatic reaction is calculated from three independent experiments. Only the values included in the linear part of the sigmoid are retained for linear regression analysis.

ii) Measurement of the tyrosine phosphatase activity of the CD45 enzyme:

- 25 Measurement of the tyrosine phosphatase activity of CD45 is based on the dephosphorylation of the peptide pp60^{C-src} by CD45. Only the cytoplasmic domain of purified human CD45 enzyme (amino acids 584 to 1281, molecular weight = 95 kDa) expressed in a yeast expression system is used for the measurement. The substrate is a synthetic peptide based on the sequence of the negative regulatory domain of pp60^{C-src}.
- 30 The released phosphate is measured by a malachite green type reagent.

The reaction is carried out in 384-well plate format with a final volume of 20 μ l. The substrate pp60^{C-src} (P-301, BIOMOL, Plymouth Meeting, PA, USA) is diluted to a

concentration of 925 μ M in the following reaction buffer: 50 mM Hepes pH 7.2; 1 mM EDTA; 1 mM of dithiothreitol (DTT); 0.05% NP-40 surfactant. The final substrate concentration is 185 μ M. The candidate products are tested in a range of decreasing concentrations starting from 160 μ M. The reaction is initiated by adding CD45 (SE-135, BIOMOL, Plymouth Meeting, PA, USA) at 15 U/ μ l (1 U = 1 pmol/min) diluted in reaction buffer. The final enzyme concentration is 1.75 U/ μ l. After incubation for 1 hour at 30°C, BIOMOL Green Reagent (AK-111, BIOMOL, Plymouth Meeting, PA, USA) is added in a volume of 50 μ l / well. After 20 to 30 minutes during which the colour develops, the absorbance at 620 nm is read using a Victor² plate reader (EGG-Wallac). Determination of the 50% inhibitory concentration of the enzyme reaction is calculated from three independent experiments.

iii) *Characterization of the antiproliferative activity:*

By way of example, the effect of a treatment on two human cell lines Mia-Paca2 and DU145 by the compounds of the examples described previously will be studied. The cell lines DU145 (human prostate cancer cells) and Mia-PaCa2 (human pancreas cancer cells) were acquired from the American Tissue Culture Collection (Rockville, Maryland, USA). The cells placed in 80 μ l of Dulbecco's Modified Eagle's medium (Gibco-Brl, Cergy-Pontoise, France) completed with 10% foetal calf serum inactivated by heating (Gibco-Brl, Cergy-Pontoise, France), 50,000 units/l of penicillin and 50 mg/l of streptomycin (Gibco-Brl, 10378-057, Cergy-Pontoise, France), and 2 mM of glutamine (Gibco-Brl, Cergy-Pontoise, France) were seeded on a 96-well plate on day 0. The cells were treated on day 1 for 96 hours with increasing concentrations of each of the compounds to be tested up to 10 μ M. At the end of this period, quantification of cell proliferation is evaluated by a colorimetric test based on the cleavage of the tetrazolium salt WST1 by the mitochondrial dehydrogenases in viable cells leading to the formation of formazan (Boehringer Mannheim, Meylan, France). These tests are carried out in duplicate with 8 determinations per concentration tested. For each compound to be tested, the values included in the linear part of the sigmoid were retained for a linear regression analysis and used to estimate the inhibitory concentration IC₅₀. The products are solubilized in dimethylsulphoxide (DMSO) at 10⁻² M and finally used in culture with 0.1% DMSO.


Results of the tests

a) The compounds of Examples 1 to 7 have an IC₅₀ less than or equal to 10 μ M on the phosphatase activity of the purified Cdc25-C recombinant enzyme.


- b) The compounds of Examples 1 to 7 have an IC_{50} less than or equal to 10 μ M on the cell proliferation of the Mia-Paca2 lines.
- c) The compounds of Examples 1 to 7 have a IC_{50} less than or equal to 10 μ M on the cell proliferation of the DU-145 lines.

Claims

1. Process for the preparation of a compound of general formula (I)₁

(I)₁

or of a compound of general formula (I)₂

(I)₂

in which:

- 5 W represents a sulphur atom in general formula (I)₁ and an oxygen atom in general formula (I)₂,
- R¹ represents a hydrogen atom or an alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, -(CH₂)-X-Y, -(CH₂)-Z-NR⁵R⁶ radical or a -CHR³⁵R³⁶ radical in which R³⁵ and R³⁶ form together with the carbon atom which carries them an indanyl or tetralinyl radical, or also
- 10 R³⁵ and R³⁶ form together with the carbon atom which carries them a saturated heterocycle containing 5 to 7 members and 1 to 2 heteroatoms chosen from O, N and S, the nitrogen atoms of said heterocycle being optionally substituted by radicals chosen from the alkyl radicals and the benzyl radical,

R¹ also being able, when W represents O, to represent moreover a carbocyclic aryl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl or alkoxy radical,

5 X representing a bond or a linear or branched alkylene radical containing 1 to 5 carbon atoms,

Y representing a saturated carbon-containing cyclic system containing 1 to 3 condensed rings chosen independently from rings with 3 to 7 members, or Y representing a saturated heterocycle containing 1 to 2 heteroatoms chosen independently from O, N and S and attached to the X radical by an N or CH member, said saturated heterocycle
10 containing moreover 2 to 6 additional members chosen independently from -CHR⁷-, -CO-, -NR⁸-, -O- and -S-, R⁷ representing a hydrogen atom or an alkyl radical and R⁸ representing a hydrogen atom or an alkyl or aralkyl radical, or also Y representing a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 3 times by substituents chosen independently from the group constituted by a halogen atom, an
15 alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, the phenyl radical, an SO₂NHR⁹ radical and an NR¹⁰R¹¹ radical, R⁹ representing a hydrogen atom or an alkyl or phenyl radical, and R¹⁰ and R¹¹ independently representing alkyl radicals,

20 Z representing a bond or a linear or branched alkylene radical containing 1 to 5 carbon atoms,

R⁵ and R⁶ being chosen independently from a hydrogen atom, an alkyl, aralkyl or -(CH₂)_n-OH radical in which n represents an integer from 1 to 6,

or R⁵ representing an alkoxycarbonyl, haloalkoxycarbonyl or aralkoxycarbonyl radical and R⁶ representing a hydrogen atom or a methyl radical,

25 or also R⁵ and R⁶ forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the -CR¹²R¹³-, -O-, -S- and -NR¹⁴- radicals, R¹² and R¹³ independently representing each time that they occur a hydrogen atom or an alkyl radical, and R¹⁴ representing a hydrogen atom or an alkyl or
30 aralkyl radical, or also R¹⁴ representing a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,

R² representing a hydrogen atom or an alkyl or aralkyl radical;

or also R¹ and R² forming together with the nitrogen atom a heterocycle with 4 to 8
35 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the -CR¹⁵R¹⁶-, -O-, -S- and -NR¹⁷- radicals, R¹⁵ and R¹⁶ independently representing each time that they occur a

hydrogen atom or an alkyl radical, and R¹⁷ representing a hydrogen atom or an alkyl or aralkyl radical; and

R⁴ represents an alkyl, cycloalkyl, cycloalkylalkyl, cyano, amino, -CH₂-COOR¹⁸, -CH₂-CO-NR¹⁹R²⁰ or -CH₂-NR²¹R²² radical, or R⁴ represents a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 4 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl, alkoxy, haloalkoxy or NR³⁷R³⁸ radical, or also R⁴ represents a phenyl radical possessing two substituents which form together a methylenedioxy or ethylenedioxy radical,

R¹⁸ representing a hydrogen atom or an alkyl radical,

R¹⁹ representing a hydrogen atom, an alkyl radical or an aralkyl radical the aryl group of which is optionally substituted 1 to 3 times by substituents chosen independently from the group constituted by a halogen atom, an alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, the phenyl radical, an SO₂NHR²³ radical and an NR²⁴R²⁵ radical, R²³ representing a hydrogen atom or an alkyl or phenyl radical, and R²⁴ and R²⁵ independently representing alkyl radicals,

R²⁰ representing a hydrogen atom or an alkyl radical,

or also R¹⁹ and R²⁰ forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the -CR²⁶R²⁷-, -O-, -S- and -NR²⁸- radicals, R²⁶ and R²⁷ independently representing each time that they occur a hydrogen atom or an alkyl radical, and R²⁸ representing a hydrogen atom or an alkyl or aralkyl radical, or also R²⁸ representing a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,

R²¹ representing a hydrogen atom, an alkyl radical or an aralkyl radical the aryl group of which is optionally substituted 1 to 3 times by substituents chosen independently from the group constituted by a halogen atom, an alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, the phenyl radical, an SO₂NHR²⁹ radical and an NR³⁰R³¹ radical, R²⁹ representing a hydrogen atom or an alkyl or phenyl radical, and R³⁰ and R³¹ independently representing alkyl radicals,


R²² representing a hydrogen atom or an alkyl radical,

or also R²¹ and R²² forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the -CR³²R³³-, -O-, -S- and -NR³⁴- radicals, R³² and R³³ independently representing each time that they occur a

hydrogen atom or an alkyl radical, and R^{34} representing a hydrogen atom, an alkyl or aralkyl radical, or also R^{34} representing a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,

- 5 R^{37} and R^{38} being chosen independently from a hydrogen atom and an alkyl radical or R^{37} and R^{38} forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the $-CR^{39}R^{40}-$, $-O-$, $-S-$ and $-NR^{41}-$ radicals, R^{39} and R^{40} independently representing each time that they occur a hydrogen atom or an alkyl radical,
- 10 R^{41} representing a hydrogen atom or an alkyl radical,

said process being characterized in that the compound of general formula (A)




(A)


in which W represents a sulphur atom or an oxygen atom and R^4 has the same meaning as in general formula (I)₁ or (I)₂ is reacted with an amine of general formula R^1R^2NH in a protic solvent.

- 15 2. Process according to claim 1, characterized in that the compound of general formula (I)₁ or (I)₂ is such that:
- R^1 represents a $-(CH_2)-Z-NR^5R^6$ radical;
 - R^2 represents a hydrogen atom; and
 - R^4 represents an alkyl radical or also a phenyl, pyridyl, thienyl or furanyl radical optionally substituted by 1 to 4 halogen atoms or by an $NR^{37}R^{38}$ radical.
- 20 3. Process for the preparation of a compound of general formula (I)₃

- 43 -

(I)₃

or of a compound of general formula (I)₄

(I)₄

in which:

W represents a sulphur atom in general formula (I)₃ and an oxygen atom in general formula (I)₄,

- 5 R¹ represents a hydrogen atom or an alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, -(CH₂)-X-Y, -(CH₂)-Z-NR⁵R⁶ radical or a -CHR³⁵R³⁶ radical in which R³⁵ and R³⁶ form together with the carbon atom which carries them an indanyl or tetralinyl radical, or also R³⁵ and R³⁶ form together with the carbon atom which carries them a saturated heterocycle containing 5 to 7 members and 1 to 2 heteroatoms chosen from O, N and S, the nitrogen atoms of said heterocycle being optionally substituted by radicals chosen from the alkyl radicals and the benzyl radical,
- 10 R¹ also being able, when W represents O, to represent moreover a carbocyclic aryl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl or alkoxy radical,
- 15 X representing a bond or a linear or branched alkylene radical containing 1 to 5 carbon atoms,
- Y representing a saturated carbon-containing cyclic system containing 1 to 3 condensed rings chosen independently from rings with 3 to 7 members, or Y representing a saturated heterocycle containing 1 to 2 heteroatoms chosen independently from O, N and S and attached to the X radical by an N or CH member, said saturated heterocycle
- 20

- containing moreover 2 to 6 additional members chosen independently from $-\text{CHR}^7-$, $-\text{CO}-$, $-\text{NR}^8-$, $-\text{O}-$ and $-\text{S}-$, R^7 representing a hydrogen atom or an alkyl radical and R^8 representing a hydrogen atom or an alkyl or aralkyl radical, or also Y representing a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 3 times by
- 5 substituents chosen independently from the group constituted by a halogen atom, an alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, the phenyl radical, an SO_2NHR^9 radical and an $\text{NR}^{10}\text{R}^{11}$ radical, R^9 representing a hydrogen atom or an alkyl or phenyl radical, and R^{10} and R^{11} independently representing alkyl radicals,
- 10 Z representing a bond or a linear or branched alkylene radical containing 1 to 5 carbon atoms,
- R^5 and R^6 being chosen independently from a hydrogen atom, an alkyl, aralkyl or $-(\text{CH}_2)_n-\text{OH}$ radical in which n represents an integer from 1 to 6,
- or R^5 representing an alkoxycarbonyl, haloalkoxycarbonyl or aralkoxycarbonyl radical
- 15 and R^6 representing a hydrogen atom or a methyl radical,
- or also R^5 and R^6 forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the $-\text{CR}^{12}\text{R}^{13}-$, $-\text{O}-$, $-\text{S}-$ and $-\text{NR}^{14}-$ radicals, R^{12} and R^{13} independently representing each time that they occur a
- 20 hydrogen atom or an alkyl radical, and R^{14} representing a hydrogen atom or an alkyl or aralkyl radical, or also R^{14} representing a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,
- R^2 representing a hydrogen atom or an alkyl or aralkyl radical;
- 25 or also R^1 and R^2 forming together with the nitrogen atom a heterocycle with 4 to 8 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the $-\text{CR}^{15}\text{R}^{16}-$, $-\text{O}-$, $-\text{S}-$ and $-\text{NR}^{17}-$ radicals, R^{15} and R^{16} independently representing each time that they occur a hydrogen atom or an alkyl radical, and R^{17} representing a hydrogen atom or an alkyl or
- 30 aralkyl radical; and
- R^4 represents an alkyl, cycloalkyl, cycloalkylalkyl, cyano, amino, $-\text{CH}_2-\text{COOR}^{18}$, $-\text{CH}_2-\text{CO}-\text{NR}^{19}\text{R}^{20}$ or $-\text{CH}_2-\text{NR}^{21}\text{R}^{22}$ radical, or R^4 represents a carbocyclic or heterocyclic aryl radical optionally substituted 1 to 4 times by substituents chosen independently from a halogen atom and an alkyl, haloalkyl, alkoxy,
- 35 haloalkoxy or $\text{NR}^{37}\text{R}^{38}$ radical, or also R^4 represents a phenyl radical possessing two substituents which form together a methylenedioxy or ethylenedioxy radical,
- R^{18} representing a hydrogen atom or an alkyl radical,

R¹⁹ representing a hydrogen atom, an alkyl radical or an aralkyl radical the aryl group of which is optionally substituted 1 to 3 times by substituents chosen independently from the group constituted by a halogen atom, an alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, the phenyl radical, an SO₂NHR²³ radical and an NR²⁴R²⁵ radical, R²³ representing a hydrogen atom or an alkyl or phenyl radical, and R²⁴ and R²⁵ independently representing alkyl radicals,

R²⁰ representing a hydrogen atom or an alkyl radical,

or also R¹⁹ and R²⁰ forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the -CR²⁶R²⁷-, -O-, -S- and -NR²⁸- radicals, R²⁶ and R²⁷ independently representing each time that they occur a hydrogen atom or an alkyl radical, and R²⁸ representing a hydrogen atom or an alkyl or aralkyl radical, or also R²⁸ representing a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,

R²¹ representing a hydrogen atom, an alkyl radical or an aralkyl radical the aryl group of which is optionally substituted 1 to 3 times by substituents chosen independently from the group constituted by a halogen atom, an alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, the phenyl radical, an SO₂NHR²⁹ radical and an NR³⁰R³¹ radical, R²⁹ representing a hydrogen atom or an alkyl or phenyl radical, and R³⁰ and R³¹ independently representing alkyl radicals,


R²² representing a hydrogen atom or an alkyl radical,

or also R²¹ and R²² forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the -CR³²R³³-, -O-, -S- and -NR³⁴- radicals, R³² and R³³ independently representing each time that they occur a hydrogen atom or an alkyl radical, and R³⁴ representing a hydrogen atom, an alkyl or aralkyl radical, or also R³⁴ representing a phenyl radical optionally substituted 1 to 3 times by substituents chosen independently from a halogen atom and an alkyl or alkoxy radical,

R³⁷ and R³⁸ being chosen independently from a hydrogen atom and an alkyl radical or R³⁷ and R³⁸ forming together with the nitrogen atom a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, the members necessary to complete the heterocycle being chosen independently from the -CR³⁹R⁴⁰-, -O-, -S- and -NR⁴¹- radicals, R³⁹ and R⁴⁰ independently representing each time that they occur a

hydrogen atom or an alkyl radical, and R⁴¹ representing a hydrogen atom or an alkyl radical;

said process being characterized in that the compound of general formula (K)



(K)

5 in which W represents a sulphur atom or an oxygen atom and R⁴ has the same meaning as in general formula (I)₃ or (I)₄ is reacted with an amine of general formula R¹R²NH in a protic solvent.

4. Process according to claim 3, characterized in that the compound of general formula (I)₃ or (I)₄ is such that:

- R¹ represents a -(CH₂)-Z-NR⁵R⁶ radical;
- 10 • R² represents a hydrogen atom; and
- R⁴ represents an alkyl radical or also a phenyl, pyridyl, thienyl or furanyl radical optionally substituted by 1 to 4 halogen atoms or by an NR³⁷R³⁸ radical

5. Compound of the general formulae (I)₁ as defined in claim 1 chosen from the following compounds:

- 15 - 2-(2,6-difluorophenyl)-5-{[2-(dimethylamino)ethyl]amino}-1,3-benzothiazole-4,7-dione;
- 2-(2,5-dichlorothien-3-yl)-5-{[2-(dimethylamino)ethyl]amino}-1,3-benzothiazole-4,7-dione;
- 2-(2,5-dichlorothien-3-yl)-5-[(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazole-
- 20 4,7-dione;
- 5-{[2-(dimethylamino)ethyl]amino}-2-(4-fluorophenyl)-1,3-benzothiazole-4,7-dione;
- 2-(4-fluorophenyl)-5-[(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazole-4,7-dione;

- 2-(2-chloro-6-fluorophenyl)-5-{[2-(dimethylamino)ethyl]amino}-1,3-benzothiazole-4,7-dione;

- 2-(2-chloro-6-fluorophenyl)-5-[(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazole-4,7-dione;

5 or a salt of one of the latter.

6. As a medicament, a compound chosen from the compounds of claim 7, or a pharmaceutically acceptable salt of one of these compounds.

7. Use of a compound according to claim 5, or of a pharmaceutically acceptable salt of one of these compounds, for preparing a medicament intended to treat cancer.

10 8. Use according to claim 7, characterized in that the cancer is chosen from breast cancer, lymphomas, cancers of the neck and head, lung cancer, cancer of the colon, prostate cancer and cancer of the pancreas.

9. As a novel industrial product, a compound of general formula **(A)** as defined in claim 1,

15 it being understood however that if W represents a sulphur atom then R⁴ is not methyl, or a salt of the latter.

10. As a novel industrial product, a compound of general formula **(K)** as defined in claim 3,

20 it being understood however that if W represents a sulphur atom then R⁴ is not the phenyl group, or a salt of the latter.

INPI
National Institute of
Industrial Property

PATENT OF INVENTION
Utility certificate
Intellectual property code – Book VI

cerfa No 11235 02

5 **Patent Department**
26 bis, rue de Saint Petersburg
7500 Paris Cedex 08
Tel: 01 53 04 53 04 Fax: 01 42 93 59 30

Designation of inventor(s) Page no. 1/2
(If the applicant is not the inventor or
the sole inventor)

This form must be completed clearly in black ink

DB 113 W /260899

Your references for this file (optional)		RS 337 – ER/MM
National registration no.		0307648
Title of the invention (200 characters or spaces maximum) Benzothiazole-4,7-diones and benzooxazole-4,7-diones substituted in position 5 or 6 and processes for their preparation		
Applicant(s): SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 42 rue du Docteur Blanche 75016 PARIS FRANCE		
Designate(s) as inventor(s): (Indicate top right "Page no. 1/1". If there are more than three inventors, use an identical form and number each page, indicating the total number of pages).		
Name		GALCERA CONTOUR
First names		Marie-Odile
Address	Street	2 allée Jacques Anquetil
	Post code and town	91070 BONDOUFLE
Member company (optional)		
Name		LAVERGNE
First names		Olivier
Address	Street	9 All@ee de la Butte de Rheims
	Post code and town	91120 PALAISEAU
Member company (optional)		
Name		
First names		
Address	Street	
	Post code and town	
Member company (optional)		
DATE AND SIGNATURE(S) OF APPLICANT(S) OR REPRESENTATIVE (Name and capacity of signatory) Paris, 16th June 2003 André BOURGOUIN, Representative		